Business UpdateJul 21, 2026, 07:26 AM
Alterity Therapeutics CEO to Attend BTIG Biotech Conference
AI Summary
Alterity Therapeutics announced that its Chief Executive Officer, David Stamler, M.D., will participate in the BTIG Biotechnology Conference 2026, taking place virtually on July 28-29, 2026. During the conference, Dr. Stamler is scheduled to host one-on-one meetings with investors in the United States. The company, a clinical-stage biotechnology firm, is focused on developing treatments for neurodegenerative diseases, with its lead asset ATH434 preparing for a Phase 3 pivotal trial in Multiple System Atrophy (MSA) following positive Phase 2 results.
Key Highlights
- Alterity Therapeutics CEO to attend BTIG Biotechnology Conference 2026.
- Dr. Stamler will host 1-on-1 meetings with investors in the United States.
- The virtual conference is scheduled for July 28-29, 2026.
- Alterity is a clinical-stage biotech focused on neurodegenerative diseases.
- Lead asset ATH434 is preparing for a Phase 3 pivotal trial in MSA.
- ATH434 demonstrated clinically meaningful efficacy in Phase 2 trials.
Price Impact
More from ATHE